Evidence brief · printable

Major Depressive Disorder evidence brief

One page, every section sourced. Print it or bring it on your phone.

  1. Research Tracker
  2. Evidence briefs
  3. Major Depressive Disorder

Print or save as PDF Fits on one A4 or Letter page.

Major Depressive Disorder: evidence brief

Open Source Medicine Foundation · page built 16 November 2026 · trial data searched 2026-11-16 (capped at 1,000 of 1,850 matching trials) · https://research.opensourcemed.info/briefs/major-depressive-disorder.html

Research information, not medical advice. Prepared to support a conversation with a clinician, not to choose a treatment.

Live version

Medicines with registered trials

Scale: trials listed for each medicine on the tracker's condition page, a snapshot of ClinicalTrials.gov. A trial means it is being studied, not that it works.

  • Escitalopram 5 trials
  • Liafensine (BMS-820836) 4 trials
  • Duloxetine 3 trials
  • Fluoxetine 2 trials
  • 18FAV45 1 trial
  • Amibegron (SR58611A) 1 trial

Non-drug approaches tested

Scale: trial status on ClinicalTrials.gov (completed, results posted). Status is not a result.

  • Transcranial brain stimulation (tDCS, TMS) 188 trials · 44 completed · 14 with results
  • Cognitive behavioural and related therapies 79 trials · 34 completed · 9 with results
  • Omega-3 fatty acids and fish oil 14 trials · 7 completed · 6 with results
  • Psychotherapy, counselling and peer support 43 trials · 18 completed · 3 with results
  • Education, coaching and self-management 25 trials · 13 completed · 3 with results
  • Care coordination, navigation and outreach 9 trials · 6 completed · 3 with results

Natural products (RepurpOS Moderate tier)

Scale: RepurpOS evidence tier, from linked trials and literature. Product quality and dose vary.

  • Probiotics
  • Vitamin D3
  • Magnesium
  • Vitamin B12
  • Omega-3 Fatty Acids
  • Zinc

Biomarkers reported

Direction in patients compared with the stated comparison group, as reported in the cited study.

  • 25-Hydroxyvitamin D lower · He et al. 2020
  • BDNF lower · Nobis et al. 2020
  • Cortisol higher · Nobis et al. 2020
  • CRP higher · Jarkas et al. 2024
  • Homocysteine higher · Harikaran et al. 2024
  • IL-6 higher · Jarkas et al. 2024

Trials recruiting

Status as recorded on ClinicalTrials.gov when searched (2026-11-16); check the registry for current status and eligibility.

  • Double-blind, Placebo-controlled Study in Adults With Major Depressive Disorder NCT07226661
  • A Study to Evaluate the Safety and Efficacy of ALKS 7290 as an Adjunctive Therapy… NCT07901179
  • Cognitive Dysfunction and Inflammation in Depression: Experimental Inhibition Via… NCT06136546
  • Advice of Moderate Drinking Pattern Versus Advice on Abstention on Major Disease… NCT06338215
  • Study of Neuro-Cognitive Correlates of Pediatric Anxiety Disorders NCT00018057
  • Intern Health Study 2026 NCT07685925

What we don't know yet

Gaps in registered trials, from the evidence-gap map. A gap is not a recommendation.

  • Exercise and physical activity: mood, anxiety and wellbeing 20 trials, no results posted yet
  • Neuromodulation and electrical stimulation: cognition 19 trials, no results posted yet
Sources: ClinicalTrials.gov (trials, status, posted results); RepurpOS natural-product tiers (registry trials, PubMed, reference databases); OSMF biomarker atlas where available; OSMF non-drug evidence map (590 non-drug trials for this condition). Lists are shortened; the live pages carry every entry with its source: evidence-gap map · RepurpOS · condition page · biomarker atlas. Counts change daily. Nothing here is a recommendation to start, stop or change any treatment.